Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Net Income towards Common Stockholders: 2021-2025

Historic Net Income towards Common Stockholders for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Sep 2025 value amounting to $7.4 million.

  • Arcutis Biotherapeutics' Net Income towards Common Stockholders rose 117.84% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$44.3 million, marking a year-over-year increase of 77.33%. This contributed to the annual value of -$140.0 million for FY2024, which is 46.58% up from last year.
  • Arcutis Biotherapeutics' Net Income towards Common Stockholders amounted to $7.4 million in Q3 2025, which was up 146.64% from -$15.9 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' Net Income towards Common Stockholders' 5-year high stood at $7.4 million during Q3 2025, with a 5-year trough of -$107.7 million in Q3 2022.
  • Over the past 3 years, Arcutis Biotherapeutics' median Net Income towards Common Stockholders value was -$41.5 million (recorded in 2024), while the average stood at -$39.6 million.
  • In the last 5 years, Arcutis Biotherapeutics' Net Income towards Common Stockholders crashed by 88.70% in 2022 and then skyrocketed by 117.84% in 2025.
  • Quarterly analysis of 5 years shows Arcutis Biotherapeutics' Net Income towards Common Stockholders stood at -$71.3 million in 2021, then fell by 1.03% to -$72.0 million in 2022, then grew by 7.96% to -$66.3 million in 2023, then skyrocketed by 83.72% to -$10.8 million in 2024, then spiked by 117.84% to $7.4 million in 2025.
  • Its last three reported values are $7.4 million in Q3 2025, -$15.9 million for Q2 2025, and -$25.1 million during Q1 2025.